Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 3:27 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 8,606 matching trials from the live ClinicalTrials.gov search.
Filters: Indianapolis, Indiana Clear all
Completed Phase 2 Interventional Results available

BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)

NCT01354431
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
34
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Nov 2, 2026, 3:27 PM EST
Enrolling by invitation No phase listed Observational

Long Term Follow up of the LTOG Cohort

NCT04787822
View directory record Official record
Conditions
Lung Transplant Failure and Rejection
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
13 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Nov 2, 2026, 3:27 PM EST
Active, not recruiting Phase 3 Interventional Results available

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

NCT01272037
View directory record Official record
Conditions
Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma
Interventions
Anastrozole, Exemestane, Laboratory Biomarker Analysis, Letrozole, Quality-of-Life Assessment, Systemic Chemotherapy, Tamoxifen Citrate
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
5,018 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1435
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 881 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 2, 2026, 3:27 PM EST
Completed Phase 3 Interventional Results available

Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

NCT01727713
View directory record Official record
Conditions
Tourette's Disorder, Tic Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
7 Years to 18 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
26
States / cities
Dothan, Alabama • Goodyear, Arizona • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2015 · Synced Nov 2, 2026, 3:27 PM EST
Recruiting Phase 4 Interventional

A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

NCT07633470
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Zunveyl®
Drug
Lead sponsor
Alpha Cognition, Inc
Industry
Eligibility
50 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
22
States / cities
Irvine, California • Orange, California • Aventura, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 2, 2026, 3:27 PM EST
Active, not recruiting Phase 3 Interventional

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

NCT06486441
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Sacituzumab govitecan-hziy, Doxorubicin, Paclitaxel
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older · Female only
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
57
States / cities
Little Rock, Arkansas • Duarte, California • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 2, 2026, 3:27 PM EST
Completed Phase 3 Interventional Results available

Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy

NCT00419341
View directory record Official record
Conditions
Primary Immune Deficiency
Interventions
Human Normal Immunoglobulin for Subcutaneous Administration
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
2 Years to 75 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
13
States / cities
Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Nov 2, 2026, 3:27 PM EST
Recruiting Not applicable Interventional

Leg Heat Therapy in Peripheral Artery Disease

NCT05465070
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Leg heat therapy, Sham Control
Device
Lead sponsor
Indiana University
Other
Eligibility
50 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Nov 2, 2026, 3:27 PM EST
Active, not recruiting Phase 3 Interventional

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

NCT04092283
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
829
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 549 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 2, 2026, 3:27 PM EST
Completed Phase 1Phase 2 Interventional

Versartis Trial in Children to Assess Long-Acting Growth Hormone

NCT01718041
View directory record Official record
Conditions
Pediatric Growth Hormone Deficiency
Interventions
Experimental: VRS-317
Drug
Lead sponsor
Versartis Inc.
Industry
Eligibility
3 Years to 11 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
23
States / cities
Clovis, California • Los Angeles, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Nov 2, 2026, 3:27 PM EST
Completed Not applicable Interventional Results available

REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE)

NCT00271154
View directory record Official record
Conditions
Heart Failure
Interventions
Cardiac Resynchronization Therapy (CRT) Device or Implantable Cardioverter Defibrillator (ICD) with CRT
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
34
States / cities
Huntsville, Alabama • Anchorage, Alaska • Redwood City, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2012 · Synced Nov 2, 2026, 3:27 PM EST
Active, not recruiting Phase 2 Interventional

Pembrolizumab Plus Olaparib in LA-HNSCC

NCT05366166
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Pembrolizumab, Olaparib, Cisplatin, IMRT (intensity modulated radiation therapy)
Biological · Drug · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
4
States / cities
Indianapolis, Indiana • Louisville, Kentucky • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Nov 2, 2026, 3:27 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

FMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder

NCT00596622
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium
Drug
Lead sponsor
Indiana University
Other
Eligibility
15 Years to 60 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Nov 2, 2026, 3:27 PM EST
Completed Phase 2 Interventional Results available

Nitric Oxide to Treat Pulmonary Embolism

NCT01939301
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Inhaled Nitric Oxide, Sham
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Indianapolis, Indiana • Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Nov 2, 2026, 3:27 PM EST
Terminated Phase 2 Interventional

A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.

NCT03196375
View directory record Official record
Conditions
Motor Neuron Disease
Interventions
FLX-787-ODT (orally disintegrating tablet), Placebo ODT
Drug
Lead sponsor
Flex Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
35
States / cities
Scottsdale, Arizona • Sacramento, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Nov 2, 2026, 3:27 PM EST
Completed Phase 3 Interventional

Zemplar® Capsule in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects on Hemodialysis or Peritoneal Dialysis

NCT00091975
View directory record Official record
Conditions
Kidney Disease
Interventions
Zemplar Capsule
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
16
States / cities
San Diego, California • Washington D.C., District of Columbia • Fort Meyers, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2011 · Synced Nov 2, 2026, 3:27 PM EST
Recruiting Phase 2Phase 3 Interventional

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

NCT05987241
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
Interventions
Biospecimen Collection, cfDNA or ctDNA Measurement, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Nivolumab, Questionnaire Administration, Relatlimab
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
992 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
495
States / cities
Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 374 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 2, 2026, 3:27 PM EST
Completed No phase listed Observational

Study of Blood Samples From Newborns With Down Syndrome

NCT00959283
View directory record Official record
Conditions
Myeloid Proliferations Associated With Down Syndrome
Interventions
Diagnostic Laboratory Biomarker Analysis, Pharmacological Study
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 90 Days
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
173
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 130 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Nov 2, 2026, 3:27 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study to Assess Outcomes in Women Undergoing Either Hysteroscopic Sterilization (Essure®) or Laparoscopic Tubal Sterilization

NCT03127722
View directory record Official record
Conditions
Contraception
Interventions
Blood draw, ESSURE (BAY1454032), Laparoscopic tubal sterilization
Procedure · Device
Lead sponsor
Bayer
Industry
Eligibility
21 Years and older · Female only
Enrollment
990 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
57
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Nov 2, 2026, 3:27 PM EST
Terminated Phase 3 Interventional Results available

Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea

NCT02015637
View directory record Official record
Conditions
Gonorrhea
Interventions
Delafloxacin, Ceftriaxone
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
15 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
25
States / cities
Birmingham, Alabama • Chula Vista, California • La Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Nov 2, 2026, 3:27 PM EST
Completed Phase 2 Interventional Results available

Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study

NCT05131477
View directory record Official record
Conditions
Eczema, Atopic Dermatitis
Interventions
Amlitelimab, Placebo
Drug
Lead sponsor
Kymab Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Fremont, California • Sacramento, California • Boca Raton, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Nov 2, 2026, 3:27 PM EST
Terminated Not applicable Interventional Results available

Contraception Navigator Program

NCT05691270
View directory record Official record
Conditions
Contraception, Contraceptive Usage, Health Care Utilization
Interventions
IN-Control (Birth Control Navigator Program)
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
15 Years to 19 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Nov 2, 2026, 3:27 PM EST
Active, not recruiting Phase 3 Interventional Results available

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors

NCT04082429
View directory record Official record
Conditions
Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors
Interventions
Concizumab
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older · Male only
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
12
States / cities
Los Angeles, California • Orange, California • Augusta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Nov 2, 2026, 3:27 PM EST
Completed No phase listed Observational Results available

Bridging Pediatric and Adult Biomarkers in Graft-Versus-Host Disease

NCT02194439
View directory record Official record
Conditions
Graft-Versus-Host Disease
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Nov 2, 2026, 3:27 PM EST